New Zealand markets closed

Clovis Oncology, Inc. (CLVS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.8600+0.0300 (+1.64%)
As of 01:59PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 237.86M
Enterprise value 689.53M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.33
Price/book (mrq)N/A
Enterprise value/revenue 4.42
Enterprise value/EBITDA -2.65

Trading information

Stock price history

Beta (5Y monthly) 1.58
52-week change 3-76.84%
S&P500 52-week change 316.48%
52-week high 311.1000
52-week low 31.8050
50-day moving average 32.8470
200-day moving average 34.4977

Share statistics

Avg vol (3-month) 34.12M
Avg vol (10-day) 35.28M
Shares outstanding 5118.41M
Implied shares outstanding 6N/A
Float 8128.04M
% held by insiders 11.51%
% held by institutions 148.55%
Shares short (13 Jan 2022) 426.7M
Short ratio (13 Jan 2022) 46.91
Short % of float (13 Jan 2022) 420.97%
Short % of shares outstanding (13 Jan 2022) 420.54%
Shares short (prior month 14 Dec 2021) 426.2M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sep 2021

Profitability

Profit margin -191.62%
Operating margin (ttm)-148.99%

Management effectiveness

Return on assets (ttm)-26.40%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)156.09M
Revenue per share (ttm)1.45
Quarterly revenue growth (yoy)-2.20%
Gross profit (ttm)128.39M
EBITDA -224.01M
Net income avi to common (ttm)-299.09M
Diluted EPS (ttm)-2.7810
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)171.95M
Total cash per share (mrq)1.32
Total debt (mrq)623.62M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.05
Book value per share (mrq)-1.76

Cash flow statement

Operating cash flow (ttm)-210.77M
Levered free cash flow (ttm)-127.79M